Hoffmann-La Roche
Facts
23 propertiesIdentity
- Instance of
- business, biopharmaceutical company, organization[9][10]
- Official website
- www.roche.com[21]
- Legal form
- Aktiengesellschaft[23]
Status and dates
- Inception
- October 1, 1896[18]
Location
- Country
- Switzerland[8]
- Location
- Roche Towers[14]
Industry and activity
- Product or material produced
- oseltamivir[22]
People
- Founder
- Fritz Hoffmann-La Roche[11]
- Chief executive officer
- Thomas Schinecker (2023–present)[13]
Relations
- Member of
- German-Swiss Chamber of Commerce[7]
- Owner of
- Genentech, Roche Tower[24][25]
- Parent organization or unit
- Roche Holding[20]
More facts +6
- Country of citizenship
- Switzerland[1]
- Different from
- Norda Stelo[26]
- Position held by head of the organization
- CEO of Hoffmann-La Roche[27]
- ISNI
- 0000000403741269
- Legal Entity Identifier
- 5493006QSC6RF6SEU438
- VIAF cluster ID
- 158855466
- Library of Congress Authorities ID
- n90689949
- GND ID
- 2118013-1
- GRID ID
- grid.417570.0
- Image (Wikimedia Commons)
- Basel, de Roche Turm Bau 1+2 IMG 1617 2022-05-15 14.19.jpg ↗
- ARCHON code
- 2077
- ArchINFORM person/group ID
- 48684
- BHCL UUID
- 10999a32-60e7-45b1-909a-e0478c76ccca
- Comparably company ID
- roche
- Described at URL
- wikirate.org
Show all 48 identifiers +36
- EU Participant Identification Code
- 999601782
- EU VAT number
- CH118241
- FES digital collections entity ID
- 340744
- Facebook username
- roche
- Freebase ID
- /m/02nyk6
- French National Assembly Lobbyist ID
- 2195
- Golden ID (archived)
- Roche-6E5JG
- Google Scholar organization ID
- 12446533641104548849
- HAND ID
- E8F5-59C3-5492-BBDE-7A4E
- HDS ID
- 041894
- IdRef ID
- 124952801
- Instagram username
- roche
- J9U entity ID
- 987007590179505171
- KISTI ID
- K000228619
- Kalliope-Verbund (GND) ID
- 2118013-1
- Lex ID
- Hoffmann-La_Roche
- LinkedIn company or organization ID
- roche
- LittleSis organization ID
- 44214
- Microsoft Academic ID (discontinued)
- 118019719
- Museum-digital person/organization ID
- 259571
- NE.se ID
- hoffmann-la-roche
- NL CR AUT ID
- kn20120530012, xx0070538
- OSM Name Suggestion Index ID
- roche-7872f6, roche-c22d3a
- OpenSecrets organization ID
- D000042474
- PM20 folder ID
- co/019150
- PermID
- 5000075049
- Quora topic ID
- Hoffmann-La-Roche-company, Hoffmann-La-Roche-1
- Ringgold ID
- 1529
- Swiss Enterprise Identification Number
- CHE-116.267.986
- Topic's main category
- Category:Roche
- Wellcome Collection concept ID
- bc3mz58j
- Yale LUX ID
- group/088df8d6-0df9-4052-93f0-bceac3923914
- YouTube channel ID
- UCH_ZBgtt6-8-VA52pao0SSA (2005–present)
- Zhihu topic ID
- 19935901
Has these parts 8
Employees / affiliates 5
Owned entities 4
Field of work 3
← Parent organization or unit 3
Industry 2
Instance of 2
Owner of 2
Belongs to 1
Country 1
Country of citizenship 1
Founder 1
Headquarters location 1
Legal form 1
Location of formation 1
Parent organization or unit 1
Product or material produced 1
Topic's main category 1
← Category's main topic 1
← Child organization or unit 1
← Commissioned by 1
← FactGrid item ID 1
← Manufacturer 1
← Partnership with 1
0 sources
FAQs
What awards did Hoffmann-La Roche receive?
Honors received include Public Eye People's Award[5] and Public Eye Swiss Award[6].
high ≥ 0.90 · emerging ≥ 0.65 · low below — calibrated against hand-rated truth (single-source .44 · two-source .62 · production-typical .70), so a band is a measurement, not a promise. High is rare by design: it needs both a supported assertion and an evidence sentence. A confirmed or contradicted chip is a Wikidata cross-check; no chip means Wikidata has no value for that property — the ordinary case here, and it says nothing either way. A confirm-only note marks a property whose check can never disagree (Wikidata's border and capital data is not exhaustive), so silence there is a limit of the check, not of the claim.
evidence “Columvi is part of Roche's broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development programme that also includes Lunsumio® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems.” manilatimes.net · read source
evidence “Under the terms of the agreement, Roche will acquire exclusive worldwide rights to develop, manufacture, and commercialize SIM0660.” rttnews.com · read source
evidence “Basel, 10 September 2026 - Roche (SIX:” finanznachrichten.de · read source
Show 9 low-confidence claims
Published, not hidden — scoring low is not a reason to withhold a sourced claim. A contradicted chip means Wikidata holds a different value; both are shown so you can judge.
evidence ““Scientific innovation has always been the foundation of Roche and Genentech’s success, and the United States remains one of our most important innovation hubs,”commented CEO Thomas Schinecker, as quoted in the press release.” swissinfo.ch · read source
evidence “Over more than 50 years of growth, Roche has significantly expanded its presence in Singapore to encompass its pharmaceuticals, diagnostics and manufacturing divisions.” manilatimes.net · read source
evidence “Uveitis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveitis companies, including Tarsier Pharma, Oculis Pharma, Roche, Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin, Affibody Medical, Priovant Therapeutics, and others.” prnewswire.com · read source
evidence “Uveitis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveitis companies, including Tarsier Pharma, Oculis Pharma, Roche, Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin, Affibody Medical, Priovant Therapeutics, and others.” prnewswire.com · read source
evidence “About Roche in haematology” finanznachrichten.de · read source
evidence “Uveitis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveitis companies, including Tarsier Pharma, Oculis Pharma, Roche, Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin, Affibody Medical, Priovant Therapeutics, and others.” prnewswire.com · read source
evidence “About Roche in haematology Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years;” manilatimes.net · read source
evidence “Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world.” finanznachrichten.de · read source
Reported by straitstimes.com straitstimes.com · read source